Expert hematologist-oncologist Grzegorz Nowakowski, MD, reviews data from the 5-year analysis of the L-MIND study combining tafasitamab with lenalidomide in relapsed/refractory diffuse large B-cell lymphoma.
Grzegorz S. Nowakowski, MD, Mayo Clinic
Advertisement
Articles by Grzegorz S. Nowakowski, MD, Mayo Clinic
Advertisement
Latest Updated Articles
CAR T in Transplant-Eligible and Transplant-Ineligible DLBCLSeptember 22nd 2020
RE-MIND Study in R/R DLBCLSeptember 22nd 2020
Treatment of R/R DLBCL: Beyond CAR T TherapySeptember 22nd 2020
Standard of Care for Relapsed/Refractory DLBCLSeptember 22nd 2020
Phase 2B SADAL Trial in R/R DLBCLSeptember 22nd 2020
L-MIND Study in R/R DLBCLSeptember 22nd 2020
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Capivasertib Plus Abiraterone and Prednisone for PTEN-Deficient mHSPC
2
FDA Approves Adjuvant Belzutifan Plus Pembrolizumab in ccRCC
3
Data Support Luspatercept at Maximum-Approved Dose for Transfusion-Dependent Lower-Risk MDS
4
Topline LAGOON Results Show Missed OS End Point With Lurbinectedin in Relapsed SCLC
5